Neurotoxicity Research

, Volume 32, Issue 2, pp 172–174 | Cite as

On the Role of Mining Exposure in Epigenetic Effects in Parkinson’s Disease

  • Sebastian Castillo
  • Patricia Muñoz
  • Maria Isabel Behrens
  • Fernando Diaz-Grez
  • Juan Segura-Aguilar
ORIGINAL ARTICLE

Abstract

To explore the possible influence of heavy metal mining on incidence of Parkinson’s disease (PD), global DNA methylation was assessed in blood samples from a population of PD patients (n = 45) and control subjects (n = 52) in Antofagasta neighborhood, a Chilean city built for exclusive use of mining companies. Comparisons were made with PD subjects (n = 52) and control subjects (n = 59) from Santiago Chile, a city having little association with mining. All subjects were assessed by two neurologists and PD diagnosis was based on UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria. From blood samples obtained from each individual, a decrease in global DNA methylation was observed in PD patients either exposed (49% of control, P < 0.001) or not exposed (47% of control, P < 0.001) to mining activity. Although there was no difference in levels of DNA methylation between PD patients from the two cities, there was a lower level of DNA methylation in control subjects from Santiago versus Antofagasta.

Keywords

Mining Parkinson’s disease Epigenetics Environmental factors DNA methylation 

Notes

Acknowledgements

We thank the Regional Liga of Parkinson of Antofagasta, especially the president and secretary, for the help in collection of blood samples and for providing patient information. We especially thank Maria Ester Munoz H. for the collection of blood samples. This study was supported by FONDECYT no. 1100165.

References

  1. Bouabid S, Tinakoua A, Lakhdar-Ghazal N, Benazzouz A (2015) Manganese neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission. J Neurochem. doi: 10.1111/jnc.13442 PubMedGoogle Scholar
  2. Caviedes P, Segura-Aguilar J (2001) The price of development in Chile: overcoming environmental hazards produced by heavy industrial exploitation. Neuroreport 12:A25CrossRefGoogle Scholar
  3. Chaná P, Jiménez M, Díaz V, Juri C (2013) Parkinson disease mortality rates in Chile. Rev Med Chile 141:327–331CrossRefGoogle Scholar
  4. Gunnarsson LG, Bodin L (2017) Parkinson’s disease and occupational exposures: a systematic literature review and meta-analyses. Scand J Work Environ Health. doi: 10.5271/sjweh.3641 PubMedGoogle Scholar
  5. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J. Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentralGoogle Scholar
  6. Jowaed A, Schmitt I, Kaut O, Wüllner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci 30:6355–6359CrossRefPubMedGoogle Scholar
  7. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A (2010) CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS One 5:e15522CrossRefPubMedPubMedCentralGoogle Scholar
  8. Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29:1583–1590CrossRefPubMedGoogle Scholar
  9. Rasheed MS, Tripathi S, Mishra S, Singh MP (2016) Coherent and contradictory facts, feats and fictions associated with metal accumulation in Parkinson’s disease: epicenter or outcome, yet a demigod question. Mol Neurobiol. 2016 Aug 1Google Scholar
  10. Wüllner U, Kaut O, deBoni L, Piston D, Schmitt I (2016) DNA methylation in Parkinson’s disease. J Neurochem 139(Suppl 1):108–120CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Sebastian Castillo
    • 1
  • Patricia Muñoz
    • 1
  • Maria Isabel Behrens
    • 1
  • Fernando Diaz-Grez
    • 1
  • Juan Segura-Aguilar
    • 1
  1. 1.Molecular and Clinical Pharmacology, ICBM, Faculty of MedicineUniversity of ChileSantiagoChile

Personalised recommendations